The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation One Inc; Genentech; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Catherine Tangen
No Relationships to Disclose
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; Genentech; MLI PeerView; OncLive; PER; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Research to Practice; Research to Practice; Sanofi; UroToday; UroToday
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Daiichi Sankyo Company; Genentech; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer
 
Shilpa Gupta
Stock and Other Ownership Interests - Nektar
Honoraria - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck Sharp & Dohme; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Exelixis; Janssen Oncology
Research Funding - Bristol-Myers Squibb; Merck; Pfizer; Seagen
 
Melissa Plets
No Relationships to Disclose
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst)
 
Andrea Harzstark
No Relationships to Disclose
 
Przemyslaw Twardowski
Honoraria - Astellas Medivation; Bayer; Genentech/Roche; Janssen; Sanofi/Aventis
Consulting or Advisory Role - Janssen; Sanofi/Aventis
Speakers' Bureau - Astellas Pharma; Bayer; Genentech/Roche; Janssen; Sanofi
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon; Exelixis; Omnitura
Research Funding - Lilly (Inst)
 
Dylan M. Zylla
Research Funding - Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Exact Sciences (Inst); Innate Pharma (Inst); MERCK (Inst); NEKTAR (Inst); Novartis (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst)
 
Matthew R. Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - EMD Serono; Exelixis; Horizon Pharma; Janssen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Horizon Pharma (Inst); Pfizer (Inst)
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Ellis Glenn Levine
Patents, Royalties, Other Intellectual Property - UpToDate
 
Bruce J. Roth
Consulting or Advisory Role - Merck; Seagen
Research Funding - Medivation (Inst)
 
Amir Goldkorn
Research Funding - Angle; Clearbridge Biomedics; Cynvenio Biosystems; Menarini Silicon Biosystems; RareCyte; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - I am listed as a co-inventor on a patent held jointly by USC and Caltech for a microfilter we developed for capturing live circulating tumor cells from blood.
 
Daniel A. Vaena
Honoraria - HMP
Consulting or Advisory Role - Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Eisai; EMD Serono; Exelixis; Genomic Health; Immunomedics; natera; Seagen
Research Funding - Aeglea Biotherapeutics (Inst); AstraZeneca (Inst); BioClin Therapeutics (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Compugen (Inst); Compugen (Inst); incyte (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); OBI Pharma (Inst); Peloton Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst)
 
Manish Kohli
Honoraria - Advanced Accelerator Applications
Travel, Accommodations, Expenses - Celgene
 
Tony Crispino
No Relationships to Disclose
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Merck; Novartis; Pfizer; UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Myovant Sciences; on quality; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology
 
Ian Murchie Thompson
Consulting or Advisory Role - Magforce; Profound Medical
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Exelixis; Merck; Roche
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest